WIRB-Copernicus Group Launches an Oncology-focused Institutional Review Board
The WIRB-Copernicus Group announced it has formed a new cancer-focused institutional review board, WCG Oncology.
The WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services for clinical research, announced it has formed a new cancer-focused institutional review board, WCG OncologyTM. WCG Oncology features its Expert Advisory Board, which provides strategic counsel to WCG regarding the changing oncology research landscape, covering cutting-edge theory, scientific methods, technologies, and study designs.
WCG is creating this group because it is a fast-evolving medical fields--featuring advances in gene therapy, targeted treatments, and companion diagnostics. In the past four years, WCG has reviewed more than 4,000 oncology protocols, which have substantially increased in complexity.
WCG Oncology is constituted by three dedicated IRB panels, which focus wholly on the ethical oversight of oncology research, and a cadre of expert oncological specialists to assist in the review of complex and scientifically-challenging research.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
